Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Emerging immunotherapy in pediatric lymphoma. Future Oncol 2016 Jan;12(2):257-70

Date

12/01/2015

Pubmed ID

26616565

DOI

10.2217/fon.15.282

Scopus ID

2-s2.0-84962769178   2 Citations

Abstract

Hodgkin and non-Hodgkin lymphoma collectively are the third most common cancer diagnosed in children each year. For children who relapse or have refractory disease, outcomes remain poor. Immunotherapy has recently emerged as a novel approach to treat hematologic malignancies. The field has been rapidly expanding over the past few years broadening its armamentarium which now includes monoclonal antibodies, antibody-drug conjugates and cellular therapies including bispecific T-cell engagers and chimeric antigen receptor-engineered T cells. Many of these agents are in their infancy stages and only beginning to make their mark on lymphoma treatment while others have begun to show promising efficacy in relapsed disease. In this review, the authors provide an overview of current and emerging immunotherapies in the field of pediatric lymphoma.

Author List

Erker C, Harker-Murray P, Burke MJ

Authors

Michael James Burke MD Professor in the Pediatrics department at Medical College of Wisconsin
Paul D. Harker-Murray MD, PhD Associate Professor in the Pediatrics department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Adolescent
Antibodies, Monoclonal
Antineoplastic Agents
Antineoplastic Combined Chemotherapy Protocols
Cell- and Tissue-Based Therapy
Child
Child, Preschool
Genetic Therapy
Humans
Immunomodulation
Immunotherapy
Immunotoxins
Infant
Infant, Newborn
Lymphoma
Molecular Targeted Therapy
T-Lymphocytes
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a